Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average recommendation of “Hold” by the twenty ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $115.92.
A number of analysts have commented on the company. Mizuho lifted their target price on Neurocrine Biosciences from $99.00 to $103.00 and gave the stock a “neutral” rating in a report on Tuesday, November 2nd. BMO Capital Markets assumed coverage on Neurocrine Biosciences in a report on Thursday, November 18th. They issued an “underperform” rating and a $76.00 price objective for the company. Needham & Company LLC assumed coverage on Neurocrine Biosciences in a report on Wednesday, September 22nd. They issued a “hold” rating for the company. Raymond James cut their price objective on Neurocrine Biosciences from $163.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, November 2nd. Finally, Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $130.00 to $119.00 and set an “outperform” rating for the company in a report on Tuesday, November 2nd.
In other news, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 7th. The stock was sold at an average price of $105.06, for a total value of $525,300.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 7th. The shares were sold at an average price of $104.81, for a total value of $838,480.00. The disclosure for this sale can be found here. Insiders have sold 13,987 shares of company stock worth $1,464,188 over the last quarter. 4.30% of the stock is owned by company insiders.
Neurocrine Biosciences stock opened at $87.86 on Monday. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 19.23 and a beta of 0.70. The stock has a fifty day simple moving average of $96.93 and a two-hundred day simple moving average of $95.87. Neurocrine Biosciences has a 12 month low of $84.50 and a 12 month high of $120.27. The company has a current ratio of 4.45, a quick ratio of 4.34 and a debt-to-equity ratio of 0.25.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 1st. The company reported $0.23 EPS for the quarter, missing the Zacks’ consensus estimate of $0.51 by ($0.28). The business had revenue of $296.00 million during the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a return on equity of 35.89% and a net margin of 41.59%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) EPS. On average, equities research analysts forecast that Neurocrine Biosciences will post 1.6 EPS for the current fiscal year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.
Recommended Story: What is channel trading?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.